Table 2.
Treatment characteristics of patients allocated to the REFLECT-in and REFLECT-out subgroups at baseline
| Overall (n = 205) | REFLECT-in (n = 110) | REFLECT-out (n = 95) | |
|---|---|---|---|
| Best response under lenvatinib treatment | |||
| Complete response | 1 (0.4) | 0 | 1 (1.1) |
| Partial response | 47 (22.9) | 28 (25.5) | 19 (20.0) |
| Stable disease | 69 (33.7) | 44 (40.0) | 25 (26.3) |
| Progressive disease | 43 (20.9) | 18 (16.4) | 25 (26.3) |
| End of treatment before first imaging | 38 (18.6) | 16 (14.5) | 22 (23.2) |
| No data available | 7 (3.5) | 4 (3.6) | 3 (3.1) |
| Median overall survival, months | 12.8 | 15.6 | 10.2 |
| Median progression-free survival, months | 6.4 | 8.1 | 4.8 |
| Disease control | 117 (57.1) | 71 (64.5) | 46 (48.4) |
| Overall response | 48 (23.4) | 28 (25.5) | 20 (21.1) |
| AFP reduction >20% under treatment | 57 (27.8) | 24 (21.8) | 33 (34.7) |
| Reason for end of treatment | |||
| Progression | 93 (45.5) | 51 (46.4) | 42 (44.1) |
| Adverse events | 75 (36.5) | 36 (32.7) | 39 (41.0) |
| Liver function deterioration | 30 (14.6) | 10 (9.1) | 20 (21.0) |
| Other adverse events | 45 (21.9) | 26 (23.6) | 19 (20.0) |
| Patient choice | 3 (1.4) | 2 (1.8) | 1 (1.1) |
| Others | 4 (2) | 2 (1.8) | 2 (2.2) |
| No data available | 6 (2.9) | 4 (3.6) | 2 (2.2) |
| Treatment ongoing | 24 (11.7) | 15 (13.6) | 9 (9.3) |
Lenvatinib treatment characteristics, patients stratified according to REFLECT-in and REFLECT-out.